| Detailed information |
|---|
| CancerLivER ID | 2050 |
| Biomarker | PKM2 |
| Biomarker Name/Symbol (given in Publication) | PKM2 |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | Biomarker for hypoxia in HCC and ICC tissues and validated on independent dataset |
| Experimental Condition | Moderately and well differentiated grades v/s poorly differentiated grades of HCC and ICC |
| Cancer type | Hepatocellular carcinoma, Cholangiocarcinoma |
| Regulation | Upregulated in HCC (16 fold) |
| Level of significance | p < 0.01 |
| Source | Tissue |
| PMID | 27203546 |
| Type of Biomarker | Diagnostic |
| Pathway | Aerobic Glycolytic pathway |
| Cohort | 9 liver cancer patients; Hypoxic liver cancer cells 7721, HepG2, HCCLM3, and normal hepatocyte cell 7702, embryonic kidney cell 293, and mouse embryo broblast 3T3 cell line; validation patients cohorts: HCC cohort include Negatvie (n = 22) and Positive (n = 72); ICC cohort include Negatvie (n = 43) |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC and ICC (Intrahepatic cholangiocarcinoma) |
| Year of Publication | 2016 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |